Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide

Jizhi Ni, Atsuhiko Taniguchi, Shuta Ozawa, Yukiko Hori, Yoichiro Kuninobu, Takashi Saito, Takaomi C. Saido, Taisuke Tomita, Youhei Sohma, Motomu Kanai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Toxic aggregation of amyloid peptide and protein is intimately related to a number of human diseases, including Alzheimer's disease (AD). Here, we developed biocompatible photooxygenation catalyst 9, which can selectively oxygenate and degrade the pathogenic aggregation of AD-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation. On the basis of the structure of a fluorescent Aβ probe, CRANAD-2, a bromine atom was introduced to increase the production of singlet oxygen for photooxygenation. The use of julolidine and perfluoroalkylborate moieties as electron-donor and -acceptor components, respectively, markedly enhanced the photocatalytic activity and reduced phototoxicity. Photooxygenation of aggregated Aβ by 9 under NIR irradiation in the presence of cells attenuated the cytotoxicity of Aβ. The tissue permeability of NIR enabled catalytic photooxygenation of aggregated Aβ under the mouse skin. Moreover, injection of the catalyst to the AD-model mouse brain along with NIR light irradiation led to a significant decrease in the intact Aβ level in the brain. An artificial chemical catalysis that can selectively transform toxic aggregates of peptides and proteins to non-toxic species under physiologic conditions would find therapeutic applications to treat currently- incurable amyloid diseases. Because peptide and protein aggregation generally depends on intermolecular hydrophobic interactions, covalent installation of hydrophilic oxygen atoms from aerobic oxygen to a peptide or protein (i.e., oxygenation) would decrease the aggregative property. Here, we report a biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of the peptide responsible for Alzheimer's disease (AD) under near-infrared light irradiation. The detoxicating chemical catalysis targeting aggregated amyloid-β peptide proceeded in the AD-model mouse brain. The results obtained in this study are an important step toward using artificial catalysis as a potential therapeutic strategy against amyloid diseases. A biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared light irradiation has been developed. The catalyst oxygenates Aβ embedded under the skin of a living mouse and diminishes the intact Aβ level in an AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid diseases and AD.

Original languageEnglish
Pages (from-to)807-820
Number of pages14
JournalChem
Volume4
Issue number4
DOIs
Publication statusPublished - Apr 12 2018

Fingerprint

Oxygenation
oxygenation
Amyloid
peptide
Peptides
near infrared
Alzheimer Disease
catalyst
Infrared radiation
Catalysts
Catalysis
irradiation
Agglomeration
Light
brain
Irradiation
catalysis
Poisons
Brain
Proteins

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Biochemistry
  • Environmental Chemistry
  • Chemical Engineering(all)
  • Biochemistry, medical
  • Materials Chemistry

Cite this

Ni, J., Taniguchi, A., Ozawa, S., Hori, Y., Kuninobu, Y., Saito, T., ... Kanai, M. (2018). Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide. Chem, 4(4), 807-820. https://doi.org/10.1016/j.chempr.2018.02.008

Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide. / Ni, Jizhi; Taniguchi, Atsuhiko; Ozawa, Shuta; Hori, Yukiko; Kuninobu, Yoichiro; Saito, Takashi; Saido, Takaomi C.; Tomita, Taisuke; Sohma, Youhei; Kanai, Motomu.

In: Chem, Vol. 4, No. 4, 12.04.2018, p. 807-820.

Research output: Contribution to journalArticle

Ni, J, Taniguchi, A, Ozawa, S, Hori, Y, Kuninobu, Y, Saito, T, Saido, TC, Tomita, T, Sohma, Y & Kanai, M 2018, 'Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide', Chem, vol. 4, no. 4, pp. 807-820. https://doi.org/10.1016/j.chempr.2018.02.008
Ni, Jizhi ; Taniguchi, Atsuhiko ; Ozawa, Shuta ; Hori, Yukiko ; Kuninobu, Yoichiro ; Saito, Takashi ; Saido, Takaomi C. ; Tomita, Taisuke ; Sohma, Youhei ; Kanai, Motomu. / Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide. In: Chem. 2018 ; Vol. 4, No. 4. pp. 807-820.
@article{ceba472b3bf0483ab1206da21764b1f2,
title = "Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide",
abstract = "Toxic aggregation of amyloid peptide and protein is intimately related to a number of human diseases, including Alzheimer's disease (AD). Here, we developed biocompatible photooxygenation catalyst 9, which can selectively oxygenate and degrade the pathogenic aggregation of AD-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation. On the basis of the structure of a fluorescent Aβ probe, CRANAD-2, a bromine atom was introduced to increase the production of singlet oxygen for photooxygenation. The use of julolidine and perfluoroalkylborate moieties as electron-donor and -acceptor components, respectively, markedly enhanced the photocatalytic activity and reduced phototoxicity. Photooxygenation of aggregated Aβ by 9 under NIR irradiation in the presence of cells attenuated the cytotoxicity of Aβ. The tissue permeability of NIR enabled catalytic photooxygenation of aggregated Aβ under the mouse skin. Moreover, injection of the catalyst to the AD-model mouse brain along with NIR light irradiation led to a significant decrease in the intact Aβ level in the brain. An artificial chemical catalysis that can selectively transform toxic aggregates of peptides and proteins to non-toxic species under physiologic conditions would find therapeutic applications to treat currently- incurable amyloid diseases. Because peptide and protein aggregation generally depends on intermolecular hydrophobic interactions, covalent installation of hydrophilic oxygen atoms from aerobic oxygen to a peptide or protein (i.e., oxygenation) would decrease the aggregative property. Here, we report a biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of the peptide responsible for Alzheimer's disease (AD) under near-infrared light irradiation. The detoxicating chemical catalysis targeting aggregated amyloid-β peptide proceeded in the AD-model mouse brain. The results obtained in this study are an important step toward using artificial catalysis as a potential therapeutic strategy against amyloid diseases. A biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared light irradiation has been developed. The catalyst oxygenates Aβ embedded under the skin of a living mouse and diminishes the intact Aβ level in an AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid diseases and AD.",
author = "Jizhi Ni and Atsuhiko Taniguchi and Shuta Ozawa and Yukiko Hori and Yoichiro Kuninobu and Takashi Saito and Saido, {Takaomi C.} and Taisuke Tomita and Youhei Sohma and Motomu Kanai",
year = "2018",
month = "4",
day = "12",
doi = "10.1016/j.chempr.2018.02.008",
language = "English",
volume = "4",
pages = "807--820",
journal = "Chem",
issn = "2451-9294",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide

AU - Ni, Jizhi

AU - Taniguchi, Atsuhiko

AU - Ozawa, Shuta

AU - Hori, Yukiko

AU - Kuninobu, Yoichiro

AU - Saito, Takashi

AU - Saido, Takaomi C.

AU - Tomita, Taisuke

AU - Sohma, Youhei

AU - Kanai, Motomu

PY - 2018/4/12

Y1 - 2018/4/12

N2 - Toxic aggregation of amyloid peptide and protein is intimately related to a number of human diseases, including Alzheimer's disease (AD). Here, we developed biocompatible photooxygenation catalyst 9, which can selectively oxygenate and degrade the pathogenic aggregation of AD-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation. On the basis of the structure of a fluorescent Aβ probe, CRANAD-2, a bromine atom was introduced to increase the production of singlet oxygen for photooxygenation. The use of julolidine and perfluoroalkylborate moieties as electron-donor and -acceptor components, respectively, markedly enhanced the photocatalytic activity and reduced phototoxicity. Photooxygenation of aggregated Aβ by 9 under NIR irradiation in the presence of cells attenuated the cytotoxicity of Aβ. The tissue permeability of NIR enabled catalytic photooxygenation of aggregated Aβ under the mouse skin. Moreover, injection of the catalyst to the AD-model mouse brain along with NIR light irradiation led to a significant decrease in the intact Aβ level in the brain. An artificial chemical catalysis that can selectively transform toxic aggregates of peptides and proteins to non-toxic species under physiologic conditions would find therapeutic applications to treat currently- incurable amyloid diseases. Because peptide and protein aggregation generally depends on intermolecular hydrophobic interactions, covalent installation of hydrophilic oxygen atoms from aerobic oxygen to a peptide or protein (i.e., oxygenation) would decrease the aggregative property. Here, we report a biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of the peptide responsible for Alzheimer's disease (AD) under near-infrared light irradiation. The detoxicating chemical catalysis targeting aggregated amyloid-β peptide proceeded in the AD-model mouse brain. The results obtained in this study are an important step toward using artificial catalysis as a potential therapeutic strategy against amyloid diseases. A biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared light irradiation has been developed. The catalyst oxygenates Aβ embedded under the skin of a living mouse and diminishes the intact Aβ level in an AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid diseases and AD.

AB - Toxic aggregation of amyloid peptide and protein is intimately related to a number of human diseases, including Alzheimer's disease (AD). Here, we developed biocompatible photooxygenation catalyst 9, which can selectively oxygenate and degrade the pathogenic aggregation of AD-related amyloid-β peptide (Aβ) under near-infrared (NIR) light irradiation. On the basis of the structure of a fluorescent Aβ probe, CRANAD-2, a bromine atom was introduced to increase the production of singlet oxygen for photooxygenation. The use of julolidine and perfluoroalkylborate moieties as electron-donor and -acceptor components, respectively, markedly enhanced the photocatalytic activity and reduced phototoxicity. Photooxygenation of aggregated Aβ by 9 under NIR irradiation in the presence of cells attenuated the cytotoxicity of Aβ. The tissue permeability of NIR enabled catalytic photooxygenation of aggregated Aβ under the mouse skin. Moreover, injection of the catalyst to the AD-model mouse brain along with NIR light irradiation led to a significant decrease in the intact Aβ level in the brain. An artificial chemical catalysis that can selectively transform toxic aggregates of peptides and proteins to non-toxic species under physiologic conditions would find therapeutic applications to treat currently- incurable amyloid diseases. Because peptide and protein aggregation generally depends on intermolecular hydrophobic interactions, covalent installation of hydrophilic oxygen atoms from aerobic oxygen to a peptide or protein (i.e., oxygenation) would decrease the aggregative property. Here, we report a biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of the peptide responsible for Alzheimer's disease (AD) under near-infrared light irradiation. The detoxicating chemical catalysis targeting aggregated amyloid-β peptide proceeded in the AD-model mouse brain. The results obtained in this study are an important step toward using artificial catalysis as a potential therapeutic strategy against amyloid diseases. A biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Aβ) under near-infrared light irradiation has been developed. The catalyst oxygenates Aβ embedded under the skin of a living mouse and diminishes the intact Aβ level in an AD-model mouse brain. The new catalyst is potentially applicable for the treatment of peripheral amyloid diseases and AD.

UR - http://www.scopus.com/inward/record.url?scp=85045189087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045189087&partnerID=8YFLogxK

U2 - 10.1016/j.chempr.2018.02.008

DO - 10.1016/j.chempr.2018.02.008

M3 - Article

AN - SCOPUS:85045189087

VL - 4

SP - 807

EP - 820

JO - Chem

JF - Chem

SN - 2451-9294

IS - 4

ER -